Taysha Gene Therapies Price to Book Ratio 2020-2026 | TSHA
Historical price to book ratio values for Taysha Gene Therapies (TSHA) over the last 10 years. The current price to book ratio for Taysha Gene Therapies as of May 08, 2026 is 4.98.
| Taysha Gene Therapies Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-05-11 | 6.82 | 0.00 | |
| 2026-03-31 | 4.47 | 0.00 | |
| 2025-12-31 | 5.50 | 0.00 | |
| 2025-09-30 | 3.27 | $0.80 | 4.09 |
| 2025-06-30 | 2.31 | $0.91 | 2.53 |
| 2025-03-31 | 1.39 | $0.27 | 5.18 |
| 2024-12-31 | 1.73 | $0.35 | 4.96 |
| 2024-09-30 | 2.01 | $0.43 | 4.64 |
| 2024-06-30 | 2.24 | $0.54 | 4.14 |
| 2024-03-31 | 2.87 | $0.29 | 9.97 |
| 2023-12-31 | 1.77 | $0.40 | 4.42 |
| 2023-09-30 | 3.16 | $-0.26 | -12.03 |
| 2023-06-30 | 0.66 | $-0.58 | -1.15 |
| 2023-03-31 | 0.80 | $-0.24 | -3.39 |
| 2022-12-31 | 2.26 | $0.02 | 150.67 |
| 2022-09-30 | 1.93 | $0.27 | 7.14 |
| 2022-06-30 | 3.72 | $0.80 | 4.67 |
| 2022-03-31 | 6.52 | $1.32 | 4.95 |
| 2021-12-31 | 11.65 | $2.48 | 4.70 |
| 2021-09-30 | 18.62 | $3.65 | 5.10 |
| 2021-06-30 | 21.20 | $4.86 | 4.36 |
| 2021-03-31 | 20.30 | $5.90 | 3.44 |
| 2020-12-31 | 26.54 | $6.66 | 3.99 |
| 2020-09-30 | 22.40 | $7.09 | 3.16 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.290B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |